Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.OQ)

SGYP.OQ on NASDAQ Stock Exchange Global Select Market

1.90USD
23 Feb 2018
Change (% chg)

$0.04 (+2.15%)
Prev Close
$1.86
Open
$1.86
Day's High
$1.90
Day's Low
$1.77
Volume
959,908
Avg. Vol
1,339,446
52-wk High
$5.97
52-wk Low
$1.68

Chart for

About

Synergy Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin... (more)

Overall

Beta: 1.22
Market Cap(Mil.): $468.65
Shares Outstanding(Mil.): 246.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 195.87 16.59
EPS (TTM): -- -- --
ROI: -- -0.71 35.07
ROE: -- -3.37 17.79

BRIEF-Paulson & Co Dissolves Share Stake In Sprint, Cuts In Synergy Pharmaceuticals ‍​

* PAULSON & CO CUTS SHARE STAKE IN SYNERGY PHARMACEUTICALS TO 4 MILLION SHARES FROM 24.1 MILLION SHARES - SEC FILING

Feb 14 2018

BRIEF-Synergy Pharma Meets Cash Balance Requirement

* SYNERGY PHARMACEUTICALS SAYS HAS MET CASH BALANCE REQUIREMENT TO ACCESS ADDITIONAL CAPITAL UNDER TERM LOAN AGREEMENT DATED SEPT 1, 2017 Source text for Eikon: Further company coverage:

Feb 01 2018

BRIEF-Synergy Pharmaceuticals Announces FDA Approval Of TRULANCE

* SYNERGY PHARMACEUTICALS ANNOUNCES FDA APPROVAL OF TRULANCE® (PLECANATIDE) FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN ADULTS

Jan 25 2018

BRIEF-Synergy Pharmaceuticals Appoints Troy Hamilton Chief Executive Officer

* SYNERGY PHARMACEUTICALS APPOINTS TROY HAMILTON CHIEF EXECUTIVE OFFICER

Dec 19 2017

BRIEF-CVI Investments reports a 7.9 pct passive stake in Synergy Pharmaceuticals as of Nov 13, 2017

* CVI Investments Inc reports a 7.9 percent passive stake in Synergy Pharmaceuticals Inc as of November 13, 2017 - SEC Filing‍​ Source text: (http://bit.ly/2A4qbNI) Further company coverage:

Nov 22 2017

BRIEF-Synergy Pharma announces pricing of offering of common stock and warrants

* Synergy Pharmaceuticals announces pricing of offering of common stock and warrants

Nov 13 2017

BRIEF-Synergy Pharma files for a potential mixed shelf offering ‍​

* Synergy Pharmaceuticals Inc files for a potential mixed shelf offering; size undisclosed - SEC filing ‍​ Source text: (http://bit.ly/2mihpZ2) Further company coverage:

Nov 13 2017

BRIEF-Synergy Pharmaceuticals posts Q3 loss per share $0.22

* Synergy Pharmaceuticals reports third quarter 2017 financial results and business update

Nov 09 2017

BRIEF-Synergy Pharmaceuticals secures $300 mln debt financing

* Synergy Pharmaceuticals secures $300 million debt financing

Sep 05 2017

Earnings vs. Estimates